Fig. 6

THZ1 mitigates CAR T cell-induced CRS without compromising antitumor efficacy. a Schematic of the murine CAR T cell-induced CRS model. Raji cells were intraperitoneally injected into mice and allowed to grow for 3 weeks, after which they were infused following THZ1 pretreatment. b Weight and body temperature of tumor-bearing mice after CAR T cell infusion. The weight/temperature of per mouse was normalized to the starting weight/temperature before CAR T infusion. c Serum levels of human and murine cytokines from mice at 70 h following CAR T infusion. d Tissue sections were obtained from mice on day 3 after CAR T infusion and stained with H&E. e Tumor burden and survival of mice after CAR T cell infusion. The one-way ANOVA and the log-rank Mantel-Cox was performed for statistical analysis on day 3 and day 20, respectively. f Representative plots and percentages of living F4/80+ macrophages, Ly6C+ monocytes and F4/80-Ly6C- (double negative, DN) myeloid cells in peritoneal lavage. g Representative plots and percentages of residual Raji cells in peritoneal lavage. Data are the mean ± SEM, n = 6–14 in b, n = 5-8 in e. Data are the mean ± SD, n = 6–14 in c, d and f, g. ***P < 0.001, **P < 0.01, and *P < 0.05 by two-way ANOVA in b, one-way ANOVA in c, e, and the unpaired t test in f, g. n.s.: no statistical significance